Page last updated: 2024-08-21

clopenthixol and Movement Disorders

clopenthixol has been researched along with Movement Disorders in 7 studies

Research

Studies (7)

Timeframe	Studies, this research(%)	All Research%
pre-1990	3 (42.86)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (28.57)	29.6817
2010's	2 (28.57)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bryan, EJ; Kumar, A; Purcell, MA	1
Niederhofer, H	1
NOECKER, G	1
Eerdekens, E; Eerdekens, M; Jacko, M; Turner, M	1
Kumar, A; Strech, D	1
Achté, KA; Turunen, S	1
Poeldinger, W	1

Reviews

2 review(s) available for clopenthixol and Movement Disorders

Article	Year
Zuclopenthixol dihydrochloride for schizophrenia. The Cochrane database of systematic reviews, 2017, 11-16, Volume: 11 Topics: Antipsychotic Agents; Clopenthixol; Humans; Movement Disorders; Randomized Controlled Trials as Topic; Schizophrenia	2017
Zuclopenthixol dihydrochloride for schizophrenia. The Cochrane database of systematic reviews, 2005, Oct-19, Issue:4 Topics: Antipsychotic Agents; Clopenthixol; Humans; Movement Disorders; Randomized Controlled Trials as Topic; Schizophrenia	2005

Trials

1 trial(s) available for clopenthixol and Movement Disorders

Article	Year
Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics. International clinical psychopharmacology, 2004, Volume: 19, Issue:4 Topics: Adult; Antipsychotic Agents; Clopenthixol; Delayed-Action Preparations; Dose-Response Relationship, Drug; Female; Flupenthixol; Fluphenazine; Haloperidol; Humans; Injections, Intramuscular; Male; Middle Aged; Movement Disorders; Psychiatric Status Rating Scales; Risperidone; Schizophrenia	2004

Article

Year

Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics.

International clinical psychopharmacology, 2004, Volume: 19, Issue:4

Topics: Adult; Antipsychotic Agents; Clopenthixol; Delayed-Action Preparations; Dose-Response Relationship, Drug; Female; Flupenthixol; Fluphenazine; Haloperidol; Humans; Injections, Intramuscular; Male; Middle Aged; Movement Disorders; Psychiatric Status Rating Scales; Risperidone; Schizophrenia

2004

Other Studies

4 other study(ies) available for clopenthixol and Movement Disorders

Article	Year
Tizanidine is not effective treating EPMS. Medical hypotheses, 2018, Volume: 116 Topics: Adolescent; Adult; Basal Ganglia Diseases; Biperiden; Cholinergic Antagonists; Clonidine; Clopenthixol; Female; Humans; Movement Disorders; Schizophrenia; Treatment Outcome	2018
[CLOPENTHIXOL (CIATYL). NEUROLEPTIC EFFECT WITH SPECIAL REFERENCE TO EXTRAPYRAMIDAL SYMPTOMS]. Medizinische Klinik, 1964, May-08, Volume: 59 Topics: Antipsychotic Agents; Basal Ganglia Diseases; Clopenthixol; Drug Therapy; Movement Disorders; Schizophrenia; Toxicology; Tranquilizing Agents	1964
The bucco-linguo-masticatory syndrome as a side-effect of neuroleptics therapy. The Psychiatric quarterly, 1967, Volume: 41, Issue:2 Topics: Adult; Aged; Brain Damage, Chronic; Cheek; Chlorpromazine; Chlorprothixene; Clopenthixol; Female; Haloperidol; Humans; Male; Mastication; Middle Aged; Movement Disorders; Parkinson Disease; Perphenazine; Phenothiazines; Reserpine; Thioridazine; Tongue; Tranquilizing Agents	1967
[Comparative clinical-psychiatric experiences with thiaxanthene-derivatives with special consideration of flupenthixol]. Arzneimittel-Forschung, 1967, Volume: 17, Issue:9 Topics: Adult; Chlorprothixene; Clopenthixol; Depression; Female; Humans; Male; Middle Aged; Movement Disorders; Oral Manifestations; Paranoid Disorders; Parasympatholytics; Piperazines; Schizophrenia; Tranquilizing Agents; Xanthenes	1967